logologologo
  • Home
  • Technology
  • Applications
    • FORMULATIONS
    • MATERIALS
    • DRUG DISCOVERY
    • CHEMICALS
    • BATTERIES
    • MANUFACTURING
    • SOFTWARE & DATA
    • HEALTHCARE
  • Products & Services
    • Alchemite™ Analytics
    • Alchemite™ Engine
    • Ichnite™
    • Consultancy
  • Events & Resources
    • Webinars
    • All Upcoming Events
    • White Papers
    • Publications
    • Case Studies
    • News & Press Coverage
    • Newsletters
  • About
    • About Intellegens
    • Careers
    • The Team
  • Contact
    • Request a Demo
    • Subscribe to our Newsletter
  • Home
  • Technology
  • Applications
    • FORMULATIONS
    • MATERIALS
    • DRUG DISCOVERY
    • CHEMICALS
    • BATTERIES
    • MANUFACTURING
    • SOFTWARE & DATA
    • HEALTHCARE
  • Products & Services
    • Alchemite™ Analytics
    • Alchemite™ Engine
    • Ichnite™
    • Consultancy
  • Events & Resources
    • Webinars
    • All Upcoming Events
    • White Papers
    • Publications
    • Case Studies
    • News & Press Coverage
    • Newsletters
  • About
    • About Intellegens
    • Careers
    • The Team
  • Contact
    • Request a Demo
    • Subscribe to our Newsletter

DRUG DISCOVERY

Speed up research

Reduce development costs

Accelerate drug discovery and accurately predict targets

KEY BENEFITS

  • Accelerate drug discovery
  • 'Fill in the gaps' in your database with confident results to target high-quality compounds
  • Run virtual screens to find new starting points for projects

RELATED TOPICS

  • Small molecule drug discovery
  • Biologics

Our deep learning solutions are ideal for application to drug discovery, where the available data are particularly sparse and noisy. Alchemite™ can learn simultaneously across all experimental endpoints to target high-quality compounds and prioritise experimental resources. Our technology can be applied to projects in both small molecule and biologics.

In collaboration with Optibrium, our exclusive partners in small molecule drug discovery, Alchemite™ has been demonstrated to make more effective use of limited data than conventional QSAR, and confidently highlight the most accurate predictions on which to base your decisions. For more information on small molecule drug discovery applications, please visit www.optibrium.com/augmentedchemistry.

Read our white paper on AI for drug discovery

Read white paper
Optibrium partners with Intellegens

Alchemite™ for Antimalarial Drug Discovery

Challenge: To identify a new antimalarial compound against a novel antimalarial mechanism of action. Available data covers multiple activity assays, but only a small proportion have been measured in practice.

Solution: Alchemite™ outperforms conventional QSAR and other AI models and can accurately predict bioactivity from sparse data (<10% complete).

Outcome: Alchemite™ confidently predicted a compound generated automatically by Optibrium’s StarDrop™ software. Compound synthesised and tested by the Open Source Malaria group and was the only entry that demonstrated potency against the target.

For more information on small-molecule drug discovery using Alchemite™, visit https://www.optibrium.com

Read Press Release here.

Anopheles mosquito
Alchemite Analytics

Discover how our technology can help reduce costs and accurately predict targets without the need for expensive trials

FIND OUT MORE

Related resources & news

Swipe to navigate articles

SUBSCRIBE TO OUR NEWSLETTER

Company number : 10591395 | Vat number: 267525774
Address: Eagle Labs, 28 Chesterton Road, Cambridge, United Kingdom, CB4 3AZ
Copyright 2021 Intellegens Limited - All rights reserved